The company's stock, trading around 1,630.80 on January 23, 2026, saw a recent upward movement of 1.33% [4, 15]
Older GLP-1 medications show minimal risk Liraglutide, dulaglutide, and exenatide did not show statistically significant increases in hair loss reports
Adding more context on the safety and efficacy limits of compounded products would round this out
Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease
Segal was a practicing neurosurgeon for approximately ten years, during which time he also played an active role as a participant on various state-sanctioned medical review panels designed to decrease the incidence of meritless medical malpractice cases
Cautionary Note Regarding Forward Looking Statements This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended